Science Daily2d
Trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
verywellhealth3d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Targeted Oncology4d
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
oncnursingnews5d
Common Adverse Events With Trastuzumab Deruxtecan for Breast Cancer
Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...
Targeted Oncology13d
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
ascopubs.org18d
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study
blockade with trastuzumab and pertuzumab with the current standard of care, taxane plus trastuzumab and pertuzumab, in HER2-positive metastatic breast cancer (MBC). Compared with the taxane-based ...
Healio20d
FDA approves Datroway for advanced breast cancer
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain ... history of or ongoing interstitial lung disease or pneumonitis, clinically active brain metastases, clinically significant ...
WebMD20d
FDA Approves New Treatment for Advanced Breast Cancer
The drug, known as datopotamab deruxtecan but marketed under the brand name Datroway, is intended to treat hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2 ...
Daily20d
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer
Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) ...
Labroots20d
FDA approval of new drug for hormone positive breast cancer
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...
Business Insider21d
AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...
MedCity News21d
AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer
The drug, known in development as datopotamab deruxtecan, or Dato-DXd, will be marketed under the brand name Datroway. Datroway is part of a class of therapies called antibody drug conjugates ...